These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21654521)

  • 1. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
    Grignol VP; Olencki T; Relekar K; Taylor C; Kibler A; Kefauver C; Wei L; Walker MJ; Chen HX; Kendra K; Carson WE
    J Immunother; 2011; 34(6):509-15. PubMed ID: 21654521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
    Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.
    Vihinen PP; Hernberg M; Vuoristo MS; Tyynelä K; Laukka M; Lundin J; Ivaska J; Pyrhönen S
    Melanoma Res; 2010 Aug; 20(4):318-25. PubMed ID: 20375744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
    Guenterberg KD; Grignol VP; Relekar KV; Varker KA; Chen HX; Kendra KL; Olencki TE; Carson WE
    Am J Clin Oncol; 2011 Feb; 34(1):87-91. PubMed ID: 20458209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).
    Go RS; Lee SJ; Shin D; Callister SM; Jobe DA; Conry RM; Tarhini AA; Kirkwood JM
    Clin Cancer Res; 2013 Dec; 19(23):6597-604. PubMed ID: 24122792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
    Markowitz J; Luedke EA; Grignol VP; Hade EM; Paul BK; Mundy-Bosse BL; Brooks TR; Dao TV; Kondalasula SV; Lesinski GB; Olencki T; Kendra KL; Carson WE
    J Immunother; 2014 Jan; 37(1):55-62. PubMed ID: 24316557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
    Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
    Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
    Perez DG; Suman VJ; Fitch TR; Amatruda T; Morton RF; Jilani SZ; Constantinou CL; Egner JR; Kottschade LA; Markovic SN
    Cancer; 2009 Jan; 115(1):119-27. PubMed ID: 19090009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
    Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
    J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
    Summers J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
    Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
    Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
    Yao JC; Phan A; Hoff PM; Chen HX; Charnsangavej C; Yeung SC; Hess K; Ng C; Abbruzzese JL; Ajani JA
    J Clin Oncol; 2008 Mar; 26(8):1316-23. PubMed ID: 18323556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of recombinant interferon alpha-2b and cisplatin in metastatic melanoma.
    Baekke J; Rytter C; Mouridsen H; Madsen EL; Møholt K; Bastholt L
    Acta Oncol; 2000; 39(5):625-8. PubMed ID: 11093371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
    Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
    J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.
    Tarhini AA; Moschos SJ; Lin Y; Lin HM; Sander C; Yin Y; Venhaus R; Gajewski TF; Kirkwood JM
    Melanoma Res; 2017 Aug; 27(4):342-350. PubMed ID: 28489678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.